<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3055">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389320</url>
  </required_header>
  <id_info>
    <org_study_id>covid 19 in RA</org_study_id>
    <nct_id>NCT04389320</nct_id>
  </id_info>
  <brief_title>Antimalarial and Covid 19 in Rheumatoid Arthritis</brief_title>
  <official_title>Antimalarial and Covid 19 in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment&#xD;
      of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement&#xD;
      of clinical and laboratory parameters, but their slow onset of action differ them from&#xD;
      glucocorticoids and nonsteroidal antiinflammatory agents.&#xD;
&#xD;
      Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin&#xD;
      manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately&#xD;
      active rheumatoid arthritis (RA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment&#xD;
      of rheumatoid arthritis and systemic lupus erythematosus.(1) . These compounds lead to&#xD;
      improvement of clinical and laboratory parameters, but their slow onset of action differ them&#xD;
      from glucocorticoids and nonsteroidal antiinflammatory agents.&#xD;
&#xD;
      Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin&#xD;
      manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately&#xD;
      active rheumatoid arthritis (RA).&#xD;
&#xD;
      It is difficult to carefully evaluate the onslaught of information that has emerged regarding&#xD;
      potential COVID-19 therapies within a few months' time in early 2020. A brief but detailed&#xD;
      approach regarding how to evaluate resulting evidence of a study has been presented by F.&#xD;
      Perry Wilson, MD, MSCE. By using the example of a case series of patients given&#xD;
      hydroxychloroquine plus azithromycin, he provides clinicians with a quick review of critical&#xD;
      analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2020</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>immunoglobulin mesurement</measure>
    <time_frame>1 month</time_frame>
    <description>serum level</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid patients receiving hydroxychloroquine</arm_group_label>
    <description>immunoglobulin analyses of covid 19 virus in patients already on hydroxychloroquine and relation to clinical presentation and genetics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>assess its role in the coarse of covid 19 virus infection</description>
    <arm_group_label>Rheumatoid patients receiving hydroxychloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        rheumatoid arthritis patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  rheumatoid arthritis recieving hydroxychloroquine chest infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients not used hydroxychloroquine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Manal Hassanien</name>
      <address>
        <city>Assiut</city>
        <state>Yes</state>
        <zip>7111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Manal Hassanien</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

